2009
DOI: 10.1128/aac.00749-08
|View full text |Cite
|
Sign up to set email alerts
|

New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development

Abstract: 2One-third of the world population is infected with Mycobacterium tuberculosis (MTB) and hence at risk of developing active tuberculosis (TB). Each year, 8.8 million patients are newly diagnosed with active TB and 1.6 million patients die of TB. The rapid spread of the human immunodeficiency virus (HIV) has fueled the TB epidemic, especially in sub-Saharan Africa, where 28% of TB patients are HIV positive (176). The current first-line treatment for TB is a multidrug regimen consisting of rifampin, isoniazid, p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
132
0

Year Published

2009
2009
2015
2015

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 216 publications
(136 citation statements)
references
References 162 publications
(235 reference statements)
1
132
0
Order By: Relevance
“…Indeed, since the standard of care for M. tuberculosis and HIV is treatment with combinations, the resistance potential of new single-targeted agents for treatment of those pathogens is not as problematic as it might be for more-standard pathogens. In contrast to the case with standard pathogens, a number of interesting new anti-M. tuberculosis agents are in various stages of development (229,374). Is combination therapy a feasible path for development of new single-targeted agents?…”
Section: Endogenous Versus Exogenous Resistancementioning
confidence: 99%
“…Indeed, since the standard of care for M. tuberculosis and HIV is treatment with combinations, the resistance potential of new single-targeted agents for treatment of those pathogens is not as problematic as it might be for more-standard pathogens. In contrast to the case with standard pathogens, a number of interesting new anti-M. tuberculosis agents are in various stages of development (229,374). Is combination therapy a feasible path for development of new single-targeted agents?…”
Section: Endogenous Versus Exogenous Resistancementioning
confidence: 99%
“…The early bactericidal activity of 400 mg OPC-67683 in patients with pulmonary TB was low during the first 4 days. However, from day 4 onwards, a significant decrease in CFU was seen (Van den Boogaard et al 2009;Kaiser Family Foundation 2009). OPC-67683 in multiple doses up to 400 mg was tolerated well by healthy volunteers, and no serious adverse events were reported.…”
Section: Nitro-dihydro-imidazooxazole (Opc-67683)mentioning
confidence: 99%
“…In February 2008, Bayer distributed a "Dear Doctor" letter warning physicians about rare but severe hepatological and dermatological adverse events associated with moxifloxacin. Therefore, the adverse events associated with moxifloxacin require extended evaluation (Van den Boogaard et al 2009). …”
Section: Moxifloxacin and Gatifloxacinmentioning
confidence: 99%
“…Apart from first and second generations antitubercular drugs fluoroquinolones also possess antitubercular activity and it is well accepted by the scientific community. Due to its wide distribution pattern, can easily invade to an intracellular compartment of Mycobacterium and produce strong effects like macrophages without cross-resistance to antitubercular drugs [26][27][28]. Among them, moxifloxacin resistance to MDR-TB is very low [29] and highly effective to isoniazide and rifampicin resistance cases.…”
Section: Citationmentioning
confidence: 99%